Class information for:
Level 1: CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
10101 1028 36.9 90%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
823 11253 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CRIZOTINIB Author keyword 127 58% 14% 145
2 ANAPLASTIC LYMPHOMA KINASE Author keyword 64 44% 11% 111
3 ALK Author keyword 60 33% 14% 149
4 EML4 ALK Author keyword 58 60% 6% 64
5 ROS1 Author keyword 43 63% 4% 43
6 ALK INHIBITOR Author keyword 41 81% 2% 25
7 ALECTINIB Author keyword 32 85% 2% 17
8 ALK INHIBITORS Author keyword 23 86% 1% 12
9 CRIZOTINIB RESISTANCE Author keyword 20 100% 1% 9
10 ALK REARRANGEMENT Author keyword 17 63% 2% 17

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CRIZOTINIB 127 58% 14% 145 Search CRIZOTINIB Search CRIZOTINIB
2 ANAPLASTIC LYMPHOMA KINASE 64 44% 11% 111 Search ANAPLASTIC+LYMPHOMA+KINASE Search ANAPLASTIC+LYMPHOMA+KINASE
3 ALK 60 33% 14% 149 Search ALK Search ALK
4 EML4 ALK 58 60% 6% 64 Search EML4+ALK Search EML4+ALK
5 ROS1 43 63% 4% 43 Search ROS1 Search ROS1
6 ALK INHIBITOR 41 81% 2% 25 Search ALK+INHIBITOR Search ALK+INHIBITOR
7 ALECTINIB 32 85% 2% 17 Search ALECTINIB Search ALECTINIB
8 ALK INHIBITORS 23 86% 1% 12 Search ALK+INHIBITORS Search ALK+INHIBITORS
9 CRIZOTINIB RESISTANCE 20 100% 1% 9 Search CRIZOTINIB+RESISTANCE Search CRIZOTINIB+RESISTANCE
10 ALK REARRANGEMENT 17 63% 2% 17 Search ALK+REARRANGEMENT Search ALK+REARRANGEMENT

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EML4 ALK FUSION GENE 185 60% 20% 204
2 CRIZOTINIB 141 62% 14% 145
3 EML4 ALK 129 74% 9% 96
4 ANAPLASTIC LYMPHOMA KINASE 106 40% 20% 210
5 ALK 62 37% 13% 137
6 CH5424802 61 95% 2% 20
7 CRIZOTINIB RESISTANCE 58 88% 3% 28
8 ALECTINIB 34 93% 1% 13
9 INHIBITOR CRIZOTINIB 30 100% 1% 12
10 EML4 ALK FUSION 28 60% 3% 31

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Future options for ALK-positive non-small cell lung cancer 2015 3 50 86%
Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer 2015 3 24 79%
ALK inhibitors in the treatment of advanced NSCLC 2014 23 46 78%
ALK in Lung Cancer: Past, Present, and Future 2013 76 39 59%
A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy 2015 1 32 91%
Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation 2014 15 25 76%
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients 2015 1 25 88%
The next-generation ALK inhibitors 2015 1 22 86%
Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer 2015 1 7 86%
Pharmacokinetics of crizotinib in NSCLC patients 2015 1 28 82%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 P DISTHORAC DIS 6 80% 0.4% 4
2 PATHOL PROJECT MOL TARGETS 6 36% 1.3% 13
3 BIO DRUG DISCOVERY 3 60% 0.3% 3
4 LOWE THORAC ONCOL 3 13% 1.8% 19
5 WORLDWIDE DISCOVERY 2 20% 1.0% 10
6 CANC BIOL PRECIS MED PROGRAM 1 38% 0.3% 3
7 CLIN ONCOEMATOL PEDIAT PADOVA 1 100% 0.2% 2
8 COURSE MED SCI CARDIOL P MED NEPHROL 1 100% 0.2% 2
9 ENDOSCOP SECT PNEUMOL 1 100% 0.2% 2
10 MOL ASSAY DEV 1 100% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000221509 GEFITINIB//ERLOTINIB//EGFR MUTATION
2 0.0000183386 ANAPLASTIC LARGE CELL LYMPHOMA//LYMPHOMATOID PAPULOSIS//NPM ALK
3 0.0000065763 MIDKINE//PLEIOTROPHIN//HB GAM
4 0.0000065574 BRONCHIOLOALVEOLAR CARCINOMA//BRONCHORRHEA//ATYPICAL ADENOMATOUS HYPERPLASIA
5 0.0000059222 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
6 0.0000053252 FRS3//FRS2//FGFRL1
7 0.0000052630 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
8 0.0000049759 SPLICED LEADER//TRANS SPLICING//CIRCULAR RNA
9 0.0000049415 INFLAMMATORY PSEUDOTUMOR//INFLAMMATORY MYOFIBROBLASTIC TUMOR//PLASMA CELL GRANULOMA
10 0.0000046523 INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION